Business Wire

Adtran and Iridium strengthen PNT resilience in Europe and Asia-Pacific with Satellite Time and Location technology

Share

Adtran, in partnership with Iridium Communications Inc. (NASDAQ: IRDM), today announced the European and Asia-Pacific launch of its synchronization solutions featuring Iridium® Satellite Time and Location (STL) technology, a significant step in countering growing threats to Global Navigation Satellite Systems (GNSS). Adtran’s OSA 5405-S PTP compact grandmaster clock with STL capabilities and its OSA 5400 STL module are now available to timing network operators in Western Europe, major countries in Eastern Europe, Turkey, and parts of Asia-Pacific, including the majority of Southeast Asia, Japan and South Korea. The solutions enhance the resilience and reliability of critical infrastructure, such as 5G networks, defense systems and many more. Leveraging low-Earth orbit (LEO) satellites to deliver precise and secure positioning, navigation and timing (PNT) services, the devices ensure continuous synchronization even in environments where GNSS is compromised. As a certified Iridium partner, Adtran offers the technology through two distinct purchasing options: an annual service license for optimal flexibility or bundled with equipment for long-term financial planning.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624939927/en/

Adtran’s synchronization solution featuring Iridium® STL services will bring new levels of PNT security to Europe and Asia-Pacific. (Photo: Business Wire)

“The weakness of GNSS signals is increasingly being exploited to create serious problems. As Europe, APAC and the rest of the world have become more dependent on PNT data, attacks on GNSS have only escalated, creating an urgent need to pivot away from the exclusive use of these satellites,” said Michael O’Connor, executive vice president of PNT at Iridium. “By integrating our STL service into Adtran Oscilloquartz devices and making it available across much of Europe and key areas of APAC, we’re providing network operators with valuable new options. They can choose to use our solution as a primary source of timing data in indoor environments, or they can leverage our secure, high-strength LEO signals as a backup source of PNT information when GNSS is unavailable. This offers the strongest ever safeguard against the threats that compromise so many aspects of our daily lives.”

Iridium® STL services harness the power of LEO satellites to transmit encrypted signals that are 1,000 times stronger than those of GNSS, significantly reducing vulnerability to disruptions and manipulation. The technology excels in challenging environments like urban canyons and indoor areas and can penetrate deep into buildings without the need for rooftop antennas. STL services are now a key feature of Adtran’s Oscilloquartz product lineup. The versatile OSA 5405-S PTP grandmaster clock supports STL time services and multi-constellation GNSS, as well as various other timing sources, all within a zero-trust architecture that leverages multiple diverse timing sources for enhanced resilience. Additionally, the OSA 5400 STL module extends these advanced STL/GNSS receiver capabilities to third-party equipment requiring timing, enabling precise, robust synchronization for a wide range of applications.

“We partnered with Iridium to bring the benefits of its STL services to critical timing infrastructure around the world because we share a common goal. We’re committed to making PNT networks as resilient and secure as possible. STL is a powerful solution for fortifying zero-trust architecture and ensuring reliable PNT even when GPS signals fail, making it ideal for both indoor and challenging outdoor locations. By empowering operators of mission-critical networks to access reliable timing in the most demanding environments, we’re also eliminating the need to install outdoor antennas and core through concrete, significantly reducing expenses,” commented Gil Biran, GM of Oscilloquartz, Adtran. “We’re excited to bring these advantages to so many more customers across Europe and APAC. Today’s announcement marks a significant advancement for the network operators and people of these regions, whose daily lives increasingly depend on robust PNT.”

Adtran is making STL services readily available in ways that perfectly align with the evolving needs of modern network infrastructures, offering two purchasing models designed to maximize operational flexibility and support financial planning. The ‘opex model’ provides an annual service license, which is ideal for operators that need adaptable yearly budgeting. Conversely, the ‘capex model’ bundles STL services with essential equipment for 3, 5 or 10 years, facilitating cost amortization similar to traditional GNSS systems. These options make the benefits of LEO satellite signals – whether as a robust primary timing source or a highly reliable backup to GNSS – accessible to sectors where reliable and secure PNT is paramount, including 5G, data centers, smart grids and defense.

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by
ADTRAN Holdings, Inc. 
www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240624939927/en/

Contacts

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Rhonda Lambert
+1 256 963 7450
investor@adtran.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye